JTCS KCI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Kojiro Furukawa
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Furukawa, K.
Right arrow Articles by Ohteki, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Furukawa, K.
Right arrow Articles by Ohteki, H.
Related Collections
Right arrow Cardiac - pharmacology

J Thorac Cardiovasc Surg 2004;127:1814-1815
© 2004 The American Association for Thoracic Surgery

Brief communication

Changes in platelet aggregation after suspension of aspirin therapy

Kojiro Furukawa, MDa,*, Hitoshi Ohteki, MDa

a Department of Cardiovascular Surgery, Saga Prefectural Hospital, Koseikan, Saga, Japan

Received for publication December 16, 2003; accepted for publication December 30, 2003.

* Address for reprints: Kojiro Furukawa, MD, Department of Thoracic and Cardiovascular Surgery, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga City 840-8571, Japan
furukawa@bcm.tmc.edu

The first 20% of the full text of this article appears below.

Aspirin medication is often suspended from 5 to 7 days before cardiac surgery because of the risk of increased perioperative blood loss.1 However, Dacey and colleagues2 recently reported that preoperative aspirin use among patients undergoing coronary artery bypass grafting appears to be associated with a decreased risk of mortality, without any significant increases in hemorrhage, blood product requirements, or related morbidities. Whether aspirin use or nonuse is the more efficacious strategy remains a controversial question. Furthermore, from the viewpoint of hard data, there are no clinical reports about changes in platelet aggregation after stopping aspirin.

Patients and methods

To standardize the platelet aggregation test, we used the grading curve method.3 Four concentrations (0.25, 0.5, 1.0, and 2.0 µg/mL) of collagen (an aggregation inducer) were plotted along the horizontal axis, and the corresponding percentages of aggregation (5 minutes after collagen administration) were plotted along the vertical axis. Rates of aggregation were measured with light transmission by the method of . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
 BMJHome page
Minerva
BMJ, September 11, 2004; 329(7466): E323 - E323.
[Full Text] [PDF]

Home page
 BMJHome page
Minerva
BMJ, June 19, 2004; 328(7454): 1506 - 1506.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2004 by The American Association for Thoracic Surgery.